PredictAD
FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER'S DISEASE
| Coordinatore | TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: Tekniikankatu 1 contact info |
| Nazionalità Coordinatore | Finland [FI] |
| Totale costo | 3˙908˙233 € |
| EC contributo | 2˙891˙526 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2007-2 |
| Funding Scheme | CP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-06-01 - 2011-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: Tekniikankatu 1 contact info |
FI (Tampere) | coordinator | 0.00 |
| 2 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA contact info |
FI (Kuopio) | participant | 0.00 |
| 3 |
GE HEALTHCARE LIMITED
Organization address
address: AMERSHAM PLACE contact info |
UK (LITTLE CHALFONT) | participant | 0.00 |
| 4 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: Exhibition Road, South Kensington Campus contact info |
UK (LONDON) | participant | 0.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 6 |
NEXSTIM OY*
Organization address
address: ELIMAENKATU 9 B contact info |
FI (HELSINKI) | participant | 0.00 |
| 7 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE contact info |
DK (HILLEROD) | participant | 0.00 |
| 8 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono contact info |
IT (MILANO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.nThe objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.nBy reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.